Portage Biotech Accounts Payable

The latest accounts payable for PRTG is $430K as of March 2025. That compares with $480K in the prior-year period — down 11.4% year over year. Investors often review this figure alongside Portage Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRTG's accounts payable moved from $480K to $430K — a 11.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Portage Biotech's operating scale or balance-sheet position.

A accounts payable figure of $430K for PRTG is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting PRTG's accounts payable ($430K), review year-over-year change from $480K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Portage Biotech's accounts payable against similar Energy names. You can also browse sector and industry screens on Stockcircle for a broader set of Energy companies and their key multiples and fundamentals.